Does Wegovy get rid of visceral fat — and what does the evidence actually show?

What the STEP trials measured about visceral fat specifically

Most weight-loss trials report body weight. Some measure waist circumference. A subset of the STEP programme went further, using MRI imaging and DEXA scans to look at where fat was lost. In STEP 1, published in the New England Journal of Medicine, participants on semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks. But the visceral-fat reduction was disproportionately large. Analyses from the trial programme found that visceral adipose tissue fell by roughly 35–40% from baseline in semaglutide groups, compared with around 10–15% in placebo groups given the same lifestyle support.

That gap matters clinically. Visceral fat is embedded around the liver, pancreas and intestines. It releases inflammatory cytokines, disrupts insulin signalling and is more strongly correlated with type 2 diabetes and heart disease risk than total body fat. If you want a fuller picture of how Wegovy interacts with visceral fat, including why that preferential loss is a metabolic benefit rather than a cosmetic one, that page covers the detail.

One practical habit worth building: measuring your waist at the level of your belly button, first thing in the morning before eating, once a month. It takes under a minute and gives you a simple running signal of visceral fat change alongside the scale reading. A waist above 94cm for men or 80cm for women is flagged as elevated risk by UK guidance, watching it fall is meaningful feedback.

How semaglutide acts on the fat depots that matter most

Semaglutide activates GLP-1 receptors in the brain, gut and elsewhere. The result is a sustained reduction in appetite and calorie intake, slowed gastric emptying, and changes in how the body uses stored energy. Visceral fat cells are particularly sensitive to the hormonal signals that change during calorie restriction, which is one reason they tend to shrink earlier and faster than subcutaneous deposits when energy balance shifts.

There is also evidence from animal models and mechanistic studies that GLP-1 receptor activation has a more direct effect on adipose tissue, reducing fat-cell size and shifting the inflammatory profile of visceral depots. The clinical trial imaging data are consistent with that, the reductions seen are larger than you would expect from calorie restriction alone at equivalent weight loss. You can read the patient-level overview on the NHS semaglutide medicines page, which sets out how the medicine works and what the main effects are.

For those specifically interested in how the percentage reduction in visceral fat maps against total weight lost, our page on semaglutide visceral fat reduction percentage breaks that down in more detail. The short version: the ratio favours visceral loss, which is the most clinically useful outcome.

Who qualifies for Wegovy privately, and what shapes the response

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber considers the full picture (not just BMI) including existing health conditions, current medicines and what you are trying to achieve. BMI alone does not determine approval.

Visceral fat response varies between people, and if you are wondering whether Wegovy genuinely helps with visceral fat for people in your situation, that page works through the evidence and the factors that shape individual response. Starting BMI, baseline metabolic health, how consistently the medicine is used and what dietary and activity changes accompany treatment all influence how much visceral fat shifts. The trial figures are averages. Someone who makes no dietary changes alongside treatment will likely see less visceral fat reduction than someone who pairs semaglutide with a modest, sustainable calorie deficit and regular movement. Our page on weight loss with GLP-1 medicines covers what an effective lifestyle approach alongside treatment looks like.

If you are thinking about the cost side of treatment, our Wegovy cost page sets out what private treatment typically involves and what a single transparent price should include.

Getting started: the clinical route to treatment

Wegovy is a prescription-only medicine. The only legal route in the UK is a prescription issued after a clinical assessment by a qualified prescriber. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber the same day, your answers go to a clinician, not a queue. If semaglutide is clinically appropriate, your prescription is issued and your treatment dispatched the same day you order before 12pm, arriving the next working day by DPD in plain packaging.

You can verify our pharmacy on the GPhC register, registration number 9012878. Checking that any online pharmacy you use is GPhC-registered is a quick, important step before you share health information or make a payment.

If you are already on treatment and want to understand more about how semaglutide specifically handles body-fat distribution, the page on whether semaglutide gets rid of belly fat covers the subcutaneous versus visceral distinction in depth. For a broader overview of semaglutide's evidence base, see our semaglutide treatment guide.

Ready to see whether Wegovy is suitable for you? Check your eligibility with a free consultation, reviewed the same day by one of our prescribers.